Federica Di Guardo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Federica Di Guardo has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Marco Palumbo
Department of General Surgery and Medical Surgical Specialties, University of Catania, 95123 Catania, Italy
10 shared publications Elisa Zambrotta
Department of General Surgery and Medical Surgical Specialties University of Catania Catania Italy
5 shared publications- Ferdinando Antonio Gulino
Unit of Gynecology and Obstetrics, Department of Human Pathology of Adults and Developmental Age, “G. Martino” University Hospital, 98122 Messina, Italy
5 shared publications Luisa Maria Di Gregorio
Department of Medical Surgical Specialties, Gynecology and Obstetrics Section, University of Catania, Catania, Italy
4 shared publicationsMarco Palumbo
Department of General Surgery and Medical Surgical Specialties, University of Catania
4 shared publications- Benito Chiofalo
Kore University of Enna, Cannizzaro Hospital, Department of Obstetrics and Gynecology, Catania, Italy
3 shared publications
Latest Publications
- 8 April 2024
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 29 (3) , 103-108
Correlation of sexual desire with sexual hormone binding globulin and free androgen index in women using combined contraceptives
To correlate the sexual desire levels with sexual hormone binding globulin and free androgen index in women taking different types of hormonal contraceptives (HCs) containing ethinylestradiol (EE), oestradiol valerate (E2V), 17β-oestradiol (E2), or estetrol (E4), combined or in phasic formulation with different progestogens having antiandrogenic properties. Three hundred and sixty-seven women (age range 18-46) participated in the study. SHBG and total testosterone (TT) were measured, and the Free Androgen Index (FAI) was calculated. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) questionnaires were used to assess sexual function and distress, respectively. The highest SHBG values and the lowest FAIs were obtained of women on HCs containing EE than those of women on HCs containing E2V/17β E2 or E4 (p < 0.001). Desire scores and FSFI total scores were lower in women on HCs with EE than in those using HCs containing E2V, 17β E2, or E4 (p ≤ 0.001). The women who were on HCs containing EE reported FSDS levels higher than those containing all the other types of oestrogen. Finally, sexual desire and FSFI total scores had a negative correlation with the SHBG values and a positive correlation with FAI percentage (p ≤ 0.0001). A minority of women using HCs with EE might experience a decreased sexual desire. This was not observed in women on HCs containing E2V, 17 E2, or E4. To avoid HC discontinuation, due to sexual desire reduction, HCs having minor antiandrogenic effects could be taken into consideration.
- 8 April 2024
- Published by Taylor & Francis in The European Journal of Contraception & Reproductive Health Care
- Vol. 29 (3) , 103-108
Correlation of sexual desire with sexual hormone binding globulin and free androgen index in women using combined contraceptives
To correlate the sexual desire levels with sexual hormone binding globulin and free androgen index in women taking different types of hormonal contraceptives (HCs) containing ethinylestradiol (EE), oestradiol valerate (E2V), 17β-oestradiol (E2), or estetrol (E4), combined or in phasic formulation with different progestogens having antiandrogenic properties. Three hundred and sixty-seven women (age range 18-46) participated in the study. SHBG and total testosterone (TT) were measured, and the Free Androgen Index (FAI) was calculated. The Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS) questionnaires were used to assess sexual function and distress, respectively. The highest SHBG values and the lowest FAIs were obtained of women on HCs containing EE than those of women on HCs containing E2V/17β E2 or E4 (p < 0.001). Desire scores and FSFI total scores were lower in women on HCs with EE than in those using HCs containing E2V, 17β E2, or E4 (p ≤ 0.001). The women who were on HCs containing EE reported FSDS levels higher than those containing all the other types of oestrogen. Finally, sexual desire and FSFI total scores had a negative correlation with the SHBG values and a positive correlation with FAI percentage (p ≤ 0.0001). A minority of women using HCs with EE might experience a decreased sexual desire. This was not observed in women on HCs containing E2V, 17 E2, or E4. To avoid HC discontinuation, due to sexual desire reduction, HCs having minor antiandrogenic effects could be taken into consideration.
- Open Access
- 20 January 2024
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 29 (1) , 1-14
The dilemma of the trigger timing in IVF: a review
Background: Triggering final oocyte maturation is a pivotal step in modern patient-tailored IVF/ICSI treatment, securing the optimal number of mature oocytes retrieved without compromising fertilization, embryo development, and live birth. Several factors need to be considered when deciding the time of the trigger: the size of the leading follicles, distribution of the follicular cohort, the duration of stimulation, the protocol used for stimulation, and ovarian response status. Main body: The current narrative review aims to appraise all available evidence for determining the proper time for inducing final oocyte maturation following IVF treatment. Moreover, it discusses the impact of the stimulation protocol, follicular size, and magnitude of ovarian response on choosing the proper timing for trigger. Comprehensive literature search of all available articles and relevant articles studying the criteria for timing of final oocyte maturation trigger in IVF/ICSI cycles were included in this review. It was found that leading follicles size of 16–22 mm is associated with the optimum oocyte maturation ratio, size of the remaining cohort of follicles should be ≥ 14 mm, 10–12 days of minimum length of stimulation should be auspicated in normal responders before trigger, and the timing of trigger administration should not depend solely on hormonal levels. Conclusion: In conclusion, the timing of triggering of final oocyte maturation in ICSI cycles should be individualized on a case-by-case basis.
- 20 January 2024
- Published by Springer Nature in Middle East Fertility Society Journal
- Vol. 29 (1) , 1-14
Open AccessThe dilemma of the trigger timing in IVF: a review
Background: Triggering final oocyte maturation is a pivotal step in modern patient-tailored IVF/ICSI treatment, securing the optimal number of mature oocytes retrieved without compromising fertilization, embryo development, and live birth. Several factors need to be considered when deciding the time of the trigger: the size of the leading follicles, distribution of the follicular cohort, the duration of stimulation, the protocol used for stimulation, and ovarian response status. Main body: The current narrative review aims to appraise all available evidence for determining the proper time for inducing final oocyte maturation following IVF treatment. Moreover, it discusses the impact of the stimulation protocol, follicular size, and magnitude of ovarian response on choosing the proper timing for trigger. Comprehensive literature search of all available articles and relevant articles studying the criteria for timing of final oocyte maturation trigger in IVF/ICSI cycles were included in this review. It was found that leading follicles size of 16–22 mm is associated with the optimum oocyte maturation ratio, size of the remaining cohort of follicles should be ≥ 14 mm, 10–12 days of minimum length of stimulation should be auspicated in normal responders before trigger, and the timing of trigger administration should not depend solely on hormonal levels. Conclusion: In conclusion, the timing of triggering of final oocyte maturation in ICSI cycles should be individualized on a case-by-case basis.
- Open Access
- 8 November 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 165 (3) , 948-958
Techniques and endocrine‐reproductive outcomes of ovarian transposition prior to pelvic radiotherapy in both gynecologic and non‐gynecologic cancers: A systematic review and meta‐analysis
Background: Premature ovarian failure may be a consequence of radiotherapy administered for the treatment of various female oncologic diseases. Before radiotherapy, fertility may be preserved through ovarian transposition (OT), which consists of moving the ovaries away from the radiation field.Objective: To ascertain all types of surgical techniques employed for OT, outline the endocrine and reproductive outcomes of each one, and discover if one works better than the others.Search strategy: The authors performed a systematic search of the English literature looking for all studies related to OT before radiotherapy published up to June 2023. Nine studies were included.Selection criteria: The eligible studies were assessed based on the presence of a description of the surgical technique employed for OT before pelvic radiotherapy and a report of the endocrine and reproductive outcomes.Data collection and analysis: Odds ratios (OR) with 95% confidence intervals were used to compare endocrine and reproductive outcomes The χ2 test was employed for the statistical analysis and a P value less than 0.05 was considered significant.Main results: A total of 323 female patients aged between 7 and 51 years—198 (61.3%) with non‐gynecologic cancer and 125 (38.7%) with gynecologic cancer—underwent OT, either bilateral (221, 68.4%) or unilateral (102, 31.6%), before radiotherapy. Essentially, two types of OT were employed: lateral and medial. A total of 71 (22%) patients underwent medial OT and 252 (78%) patients (127 with non‐gynecologic tumors and 125 with gynecologic tumors) had a lateral OT. The latter was used in a similar percentage of cases for gynecologic (50.4%) and non‐gynecologic (49.6%) tumors, whereas the medial approach was performed only for non‐gynecologic cancers (Hodgkin's lymphoma). The difference between medial OT and lateral OT was not significant regarding the preservation of endocrine function (OR 0.65, P = 0.120). However, midline OT worked better in terms of reproductive outcomes. In fact, the percentage of patients with pregnancy (49.2%) and live births (45%) associated with medial OT was significantly higher than that associated with lateral OT, 6.5% and 13.4%, respectively, and the difference between such data was statistically significant (OR 7.04, P = 0.001 and OR 5.29, P = 0.003, respectively).Conclusions: Ovarian transposition is an important method to preserve fertility before radiotherapy, considering the worldwide ongoing use of this treatment for various cancers arising in young women. The surgical method depends on the type of disease, but OT—especially medial OT when feasible—is effective in terms of ovarian function preservation and reproductive outcomes.
- 8 November 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 165 (3) , 948-958
Open AccessTechniques and endocrine‐reproductive outcomes of ovarian transposition prior to pelvic radiotherapy in both gynecologic and non‐gynecologic cancers: A systematic review and meta‐analysis
Background: Premature ovarian failure may be a consequence of radiotherapy administered for the treatment of various female oncologic diseases. Before radiotherapy, fertility may be preserved through ovarian transposition (OT), which consists of moving the ovaries away from the radiation field.Objective: To ascertain all types of surgical techniques employed for OT, outline the endocrine and reproductive outcomes of each one, and discover if one works better than the others.Search strategy: The authors performed a systematic search of the English literature looking for all studies related to OT before radiotherapy published up to June 2023. Nine studies were included.Selection criteria: The eligible studies were assessed based on the presence of a description of the surgical technique employed for OT before pelvic radiotherapy and a report of the endocrine and reproductive outcomes.Data collection and analysis: Odds ratios (OR) with 95% confidence intervals were used to compare endocrine and reproductive outcomes The χ2 test was employed for the statistical analysis and a P value less than 0.05 was considered significant.Main results: A total of 323 female patients aged between 7 and 51 years—198 (61.3%) with non‐gynecologic cancer and 125 (38.7%) with gynecologic cancer—underwent OT, either bilateral (221, 68.4%) or unilateral (102, 31.6%), before radiotherapy. Essentially, two types of OT were employed: lateral and medial. A total of 71 (22%) patients underwent medial OT and 252 (78%) patients (127 with non‐gynecologic tumors and 125 with gynecologic tumors) had a lateral OT. The latter was used in a similar percentage of cases for gynecologic (50.4%) and non‐gynecologic (49.6%) tumors, whereas the medial approach was performed only for non‐gynecologic cancers (Hodgkin's lymphoma). The difference between medial OT and lateral OT was not significant regarding the preservation of endocrine function (OR 0.65, P = 0.120). However, midline OT worked better in terms of reproductive outcomes. In fact, the percentage of patients with pregnancy (49.2%) and live births (45%) associated with medial OT was significantly higher than that associated with lateral OT, 6.5% and 13.4%, respectively, and the difference between such data was statistically significant (OR 7.04, P = 0.001 and OR 5.29, P = 0.003, respectively).Conclusions: Ovarian transposition is an important method to preserve fertility before radiotherapy, considering the worldwide ongoing use of this treatment for various cancers arising in young women. The surgical method depends on the type of disease, but OT—especially medial OT when feasible—is effective in terms of ovarian function preservation and reproductive outcomes.
- Open Access
- 12 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (2) , 614
Letrozole and Ovarian Hyperstimulation Syndrome (OHSS): A Promising Prevention Strategy
Ovarian Hyperstimulation Syndrome (OHSS) is an uncommon but serious complication occurring in patients undergoing ovarian stimulation. It is characterized by ovarian enlargement, nausea, vomiting, abdominal pain/distension, and reduction in urine output. However, OHSS may rarely evolve into a life-threatening condition with ascites, hemoconcentration and hypercoagulability. Prevention of OHSS consists of an integrated approach that associates behavioral aspects with administration of pharmacological compounds. Among drugs used to manage OHSS, Letrozole has recently been proposed as an effective option for prevention of the syndrome. However, despite the promising findings reported by several studies, to date Letrozole is not yet officially mentioned in the guidelines for “Prevention and Treatment of moderate and severe ovarian hyperstimulation syndrome”. In this scenario, the current study discusses Letrozole approaches scientifically available to prevent OHSS.
- 12 January 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (2) , 614
Open AccessLetrozole and Ovarian Hyperstimulation Syndrome (OHSS): A Promising Prevention Strategy
Ovarian Hyperstimulation Syndrome (OHSS) is an uncommon but serious complication occurring in patients undergoing ovarian stimulation. It is characterized by ovarian enlargement, nausea, vomiting, abdominal pain/distension, and reduction in urine output. However, OHSS may rarely evolve into a life-threatening condition with ascites, hemoconcentration and hypercoagulability. Prevention of OHSS consists of an integrated approach that associates behavioral aspects with administration of pharmacological compounds. Among drugs used to manage OHSS, Letrozole has recently been proposed as an effective option for prevention of the syndrome. However, despite the promising findings reported by several studies, to date Letrozole is not yet officially mentioned in the guidelines for “Prevention and Treatment of moderate and severe ovarian hyperstimulation syndrome”. In this scenario, the current study discusses Letrozole approaches scientifically available to prevent OHSS.
- 20 July 2022
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 39 (9) , 2069-2075
Impact of cell loss after warming of human vitrified day 3 embryos on obstetric outcome in single frozen embryo transfers
Purpose Does cell loss (CL) after vitrification and warming (V/W) of day 3 embryos have an impact on live birth rate (LBR) and neonatal outcomes? Method This retrospective analysis includes cleavage stage day 3 embryos vitrified/warmed between 2011 and 2018. Only single vitrified/warmed embryo transfers were included. Pre-implantation genetic screening, oocyte donation, and age banking were excluded from the analysis. The sample was divided into two groups: group A (intact embryo after warming) and group B (≤ 50% blastomere loss after warming). Results On the total embryos (n = 2327), 1953 were fully intact (83.9%, group A) and 374 presented cell damage (16.1%, group B). In group B, 62% (232/374) of the embryos had lost only one cell. Age at cryopreservation, cause of infertility, insemination procedure, and semen origin were comparable between the two groups. The positive hCG rate (30% and 24.3%, respectively, for intact vs CL group, p = 0.028) and LBR (13.7% and 9.4%, respectively, for intact vs CL group, p = 0.023) per warming cycle were significantly higher for intact embryos. However, LBR per positive hCG was equivalent between intact and damaged embryos (45.6% vs 38.5%, respectively, p = 0.2). Newborn measurements (length, weight, and head circumference at birth) were comparable between the two groups. Multivariate logistic regression showed that the presence of CL is not predictive for LB when adjusting for patients’ age. Conclusions LBR is significantly higher after transfer of an intact embryo compared to an embryo with CL after warming; however, neonatal outcomes are comparable between the two groups.
- 20 July 2022
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 39 (9) , 2069-2075
Impact of cell loss after warming of human vitrified day 3 embryos on obstetric outcome in single frozen embryo transfers
Purpose Does cell loss (CL) after vitrification and warming (V/W) of day 3 embryos have an impact on live birth rate (LBR) and neonatal outcomes? Method This retrospective analysis includes cleavage stage day 3 embryos vitrified/warmed between 2011 and 2018. Only single vitrified/warmed embryo transfers were included. Pre-implantation genetic screening, oocyte donation, and age banking were excluded from the analysis. The sample was divided into two groups: group A (intact embryo after warming) and group B (≤ 50% blastomere loss after warming). Results On the total embryos (n = 2327), 1953 were fully intact (83.9%, group A) and 374 presented cell damage (16.1%, group B). In group B, 62% (232/374) of the embryos had lost only one cell. Age at cryopreservation, cause of infertility, insemination procedure, and semen origin were comparable between the two groups. The positive hCG rate (30% and 24.3%, respectively, for intact vs CL group, p = 0.028) and LBR (13.7% and 9.4%, respectively, for intact vs CL group, p = 0.023) per warming cycle were significantly higher for intact embryos. However, LBR per positive hCG was equivalent between intact and damaged embryos (45.6% vs 38.5%, respectively, p = 0.2). Newborn measurements (length, weight, and head circumference at birth) were comparable between the two groups. Multivariate logistic regression showed that the presence of CL is not predictive for LB when adjusting for patients’ age. Conclusions LBR is significantly higher after transfer of an intact embryo compared to an embryo with CL after warming; however, neonatal outcomes are comparable between the two groups.
- Open Access
- 8 April 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 874628
Editorial: Recent Advances in Ovarian Stimulation
Editorial: Recent Advances in Ovarian Stimulation
- 8 April 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 874628
Open AccessEditorial: Recent Advances in Ovarian Stimulation
Editorial: Recent Advances in Ovarian Stimulation
- 28 February 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (5) , 951
Is mild stimulation the way forward?
- 28 February 2022
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 44 (5) , 951
Is mild stimulation the way forward?
- 5 January 2022
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 42 (5) , 802-808
Immersive virtual reality as tool to reduce anxiety during embryo transfer
The use of Virtual Reality (VR) has gained wide acceptance in several scientific fields. It represents an innovative technological tool providing the experience to be immersed in a non-physical world putting on head-mounted displays that surround the users with images and sounds. To date, VR has been mainly employed in the healthcare sector for educational aims, in order to provide the learners with a new method of delivering simulations. However, its application to real clinical practice has recently generated beneficial effects for patients, especially for those who experience symptoms of psychological burden. Infertile couples often struggle with anxiety and depression which have a strong impact on life quality. Furthermore, the perspective to undergo long treatments with uncertain results and an history of failed attempts may contribute to enhance patients’ negative feelings during In Vitro Fertilization (IVF) cycles until Embryo Transfer (ET). The role of VR in reducing pain and anxiety during outpatient hysteroscopy, hysterosalpingography and oocytes retrieval, has been recently investigated with satisfactory results in terms of reducing pain and anxiety levels. However, to date, inconclusive outcomes have been reported on pregnancy rate. Our study would discuss the existent literature on VR applied to current medical practice and infertility, proposing its beneficial impact on women anxiety during IVF cycle with ET.
- 5 January 2022
- Published by Taylor & Francis in Journal of Obstetrics and Gynaecology
- Vol. 42 (5) , 802-808
Immersive virtual reality as tool to reduce anxiety during embryo transfer
The use of Virtual Reality (VR) has gained wide acceptance in several scientific fields. It represents an innovative technological tool providing the experience to be immersed in a non-physical world putting on head-mounted displays that surround the users with images and sounds. To date, VR has been mainly employed in the healthcare sector for educational aims, in order to provide the learners with a new method of delivering simulations. However, its application to real clinical practice has recently generated beneficial effects for patients, especially for those who experience symptoms of psychological burden. Infertile couples often struggle with anxiety and depression which have a strong impact on life quality. Furthermore, the perspective to undergo long treatments with uncertain results and an history of failed attempts may contribute to enhance patients’ negative feelings during In Vitro Fertilization (IVF) cycles until Embryo Transfer (ET). The role of VR in reducing pain and anxiety during outpatient hysteroscopy, hysterosalpingography and oocytes retrieval, has been recently investigated with satisfactory results in terms of reducing pain and anxiety levels. However, to date, inconclusive outcomes have been reported on pregnancy rate. Our study would discuss the existent literature on VR applied to current medical practice and infertility, proposing its beneficial impact on women anxiety during IVF cycle with ET.
- Open Access
- 1 April 2021
- Vol. 15 (2) , 80-87
Hysteroscopy as An Investigational Operative Procedure in Primary and Secondary Infertility: A Systematic Review
Background: The aim of this study is to review current indications to diagnostic and/or operative hysteroscopy in primary and secondary infertility, as well as to determine its efficacy in improving fertility. Materials and Methods: We gathered available evidence about the role of hysteroscopy in the management of various infertility conditions. Literature from 2000 to 2020 that pertained to this topic were retrieved and appropriately selected. Results: Hysteroscopy does not appear as a first line diagnostic procedure for every clinical scenario. However, its diagnostic sensitivity and specificity in assessing intrauterine pathology is superior to all other non-invasive techniques, such as saline infusion/gel instillation sonography (SIS/GIS), transvaginal sonography (TVS) and hysterosalpingography (HSG). Hysteroscopy allows not only a satisfactory evaluation of the uterine cavity but also, the eventual treatment of endocavitary pathologies that may affect fertility both in spontaneous and assisted reproductive technology (ART) cycles. Conclusion: Hysteroscopy, due to its diagnostic and therapeutic potential, should be regarded as a necessary step in infertility management. However, in case of suspected uterine malformation, hysteroscopy should be integrated with other tests [three-dimensional (3D) ultrasound or magnetic resonance imaging (MRI)] for diagnostic confirmation.
- 1 April 2021
- Vol. 15 (2) , 80-87
Open AccessHysteroscopy as An Investigational Operative Procedure in Primary and Secondary Infertility: A Systematic Review
Background: The aim of this study is to review current indications to diagnostic and/or operative hysteroscopy in primary and secondary infertility, as well as to determine its efficacy in improving fertility. Materials and Methods: We gathered available evidence about the role of hysteroscopy in the management of various infertility conditions. Literature from 2000 to 2020 that pertained to this topic were retrieved and appropriately selected. Results: Hysteroscopy does not appear as a first line diagnostic procedure for every clinical scenario. However, its diagnostic sensitivity and specificity in assessing intrauterine pathology is superior to all other non-invasive techniques, such as saline infusion/gel instillation sonography (SIS/GIS), transvaginal sonography (TVS) and hysterosalpingography (HSG). Hysteroscopy allows not only a satisfactory evaluation of the uterine cavity but also, the eventual treatment of endocavitary pathologies that may affect fertility both in spontaneous and assisted reproductive technology (ART) cycles. Conclusion: Hysteroscopy, due to its diagnostic and therapeutic potential, should be regarded as a necessary step in infertility management. However, in case of suspected uterine malformation, hysteroscopy should be integrated with other tests [three-dimensional (3D) ultrasound or magnetic resonance imaging (MRI)] for diagnostic confirmation.
- 3 January 2021
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 303 (6) , 1483-1488
Poor maternal–neonatal outcomes in pregnant patients with confirmed SARS-Cov-2 infection: analysis of 145 cases
Purpose The coronavirus 2 (SARS-CoV-2) infection has recently spread causing millions of individuals affected globally. The raising mortality rate highlighted the necessity to identify the most susceptible populations, such as pregnant women and their fetuses, in order to protect them. Few studies have been conducted trying to identify maternal-neonatal outcomes among pregnant patients affected by COVID 19. In this scenario, this study aims to analyse poor maternal–neonatal outcomes in pregnant women affected by SARS-CoV-2 infection. Methods This was a double-centre, 5 months retrospective analysis conducted in Italy. The study population consisted of pregnant women with confirmed SARS-CoV-2 infection assessed by Time Quantitative Reverse Transcription PCR (qRT-PCR) nasopharyngeal swabs. Results 145 pregnant women affected by confirmed SARS-CoV-2 infection were included. Among them, 116 (80%) were symptomatic and 29 (20%) were asymptomatic. Up to half of the patients (n = 111; 76.5%) had a past history of respiratory disease. The mean gestational age at delivery was 36 weeks ± 5 days, while the mean maternal age was 31.5 ± 5.63. Reactive C protein (CRP) serum levels were higher than the normal range corresponding to a mean value of 56.93 ± 49.57 mg/L. The mean interval between the diagnosis of maternal COVID-19 infection and the delivery was 8.5 days. With regard to the type of delivery, the percentage of patients who delivered vaginally was higher than those who experienced a caesarean section. (74.4% vs 25.6%). The percentage of term birth was higher than preterm one (62% vs 38%). Finally, the percentages of maternal and neonatal death were found to be 5% and 6%, respectively; similarly, the percentage of the infection vertical transmission was 5%. Conclusion COVID-19 infection in pregnant women seems to negatively affect both maternal and neonatal outcomes. However, it is important to emphasize that most of the cases of maternal death occurred in patients with severe symptoms and highly altered parameters related to SARS-CoV-2 infection. In the future, larger studies are warranted in order to validate these findings.
- 3 January 2021
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 303 (6) , 1483-1488
Poor maternal–neonatal outcomes in pregnant patients with confirmed SARS-Cov-2 infection: analysis of 145 cases
Purpose The coronavirus 2 (SARS-CoV-2) infection has recently spread causing millions of individuals affected globally. The raising mortality rate highlighted the necessity to identify the most susceptible populations, such as pregnant women and their fetuses, in order to protect them. Few studies have been conducted trying to identify maternal-neonatal outcomes among pregnant patients affected by COVID 19. In this scenario, this study aims to analyse poor maternal–neonatal outcomes in pregnant women affected by SARS-CoV-2 infection. Methods This was a double-centre, 5 months retrospective analysis conducted in Italy. The study population consisted of pregnant women with confirmed SARS-CoV-2 infection assessed by Time Quantitative Reverse Transcription PCR (qRT-PCR) nasopharyngeal swabs. Results 145 pregnant women affected by confirmed SARS-CoV-2 infection were included. Among them, 116 (80%) were symptomatic and 29 (20%) were asymptomatic. Up to half of the patients (n = 111; 76.5%) had a past history of respiratory disease. The mean gestational age at delivery was 36 weeks ± 5 days, while the mean maternal age was 31.5 ± 5.63. Reactive C protein (CRP) serum levels were higher than the normal range corresponding to a mean value of 56.93 ± 49.57 mg/L. The mean interval between the diagnosis of maternal COVID-19 infection and the delivery was 8.5 days. With regard to the type of delivery, the percentage of patients who delivered vaginally was higher than those who experienced a caesarean section. (74.4% vs 25.6%). The percentage of term birth was higher than preterm one (62% vs 38%). Finally, the percentages of maternal and neonatal death were found to be 5% and 6%, respectively; similarly, the percentage of the infection vertical transmission was 5%. Conclusion COVID-19 infection in pregnant women seems to negatively affect both maternal and neonatal outcomes. However, it is important to emphasize that most of the cases of maternal death occurred in patients with severe symptoms and highly altered parameters related to SARS-CoV-2 infection. In the future, larger studies are warranted in order to validate these findings.